Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
A NEW study revealed that India has become the top source of foreign-born founders behind America’s most valuable start-ups, highlighting the country's growing influence in the global technology sector.
Research by Stanford University’s Venture Capital Initiative showed that Indian entrepreneurs have founded 90 "unicorn" companies - start-ups valued at over $1 billion - in the US.
According to the report, Indian Institutes of Technology (IITs) dominate the rankings, with IIT Delhi leading the pack by producing 16 unicorn founders, including Jyoti Bansal who created AppDynamics. IIT Bombay follows closely with 14 founders, while IIT Kanpur has contributed 12, including the team behind cloud computing giant Nutanix.
Among the 165 US unicorn founders who studied at Indian universities, 81 per cent pursued either computer science or engineering degrees, the report noted.
“Indian entrepreneurs have become essential to the US’s innovation economy. India has contributed 141 unicorn founders who received their undergraduate education from Indian universities, again leading all countries outside the US. Most impressively, startups founded by Indian entrepreneurs who relocate to the US are 6.5 times more likely to achieve unicorn status than the average,” author of the report, Ilya A. Strebulaev, told Eastern Eye.
This pattern of immigrant entrepreneurship isn't unique to the US. In Britain, foreign-born founders play an equally vital role in the start-up ecosystem, according to data from Financial Times-backed tracker Sifted.
Despite foreign-born residents making up less than 15 per cent of the UK's population, they account for 39 per cent of the country's 100 fastest-growing companies. The USwas the most common country of birth for foreign-born founders in the UK, followed by Italy, France, Canada, India and Germany.
Asian entrepreneurs have been particularly successful, founding major unicorns including Oxford Nanopore Technologies and Hopin. Data shows that 24 per cent of Britain's unicorn companies now have foreign-born founders, with entrepreneurs coming from 28 different countries across five continents.
According to the Stanford report, California's unicorn companies employ approximately six per cent of their workforce in India on average, making the country the largest international talent pool for these billion-dollar firms. This creates valuable professional networks that often serve as launching pads for future entrepreneurs, as employees gain industry experience before starting their own ventures.
“India's technical education system has created a "national asset" in the global knowledge economy. The success of Indian entrepreneurs in the US also strengthens India's own start-up ecosystem through knowledge transfer, investment flows, and mentorship connections. As technology continues to drive worldwide economic growth, India's position as a primary source of high-impact entrepreneurs looks set to become even more significant in the years ahead,”
Strebulaev, who is the David S. Lobel professor of private equity at Stanford Graduate School of Business, pointed out.
Immigrant entrepreneurs are not just contributing to the US’s innovation boom - they are driving it, the report said. It analysed 1,078 founders behind 500 US unicorns and found that 474 founders came from abroad, representing 65 different countries across six continents.
Beyond individual founders relocating, entire companies are moving to the US to access its unique scaling advantages. The research showed that eight per cent of US unicorns - 88 out of 1,108 companies - were initially founded elsewhere before relocating to US soil. The benefits of this move are dramatic: Israeli start-ups that relocated to the US were nine times more likely to achieve unicorn status than those that remained at home, while Indian companies saw a 6.5-fold improvement in their chances.
“Successful examples of this trend include messaging platform Slack from Canada, gaming engine Unity from Denmark, and meditation app Headspace from Britain. These companies discovered that whilst great ideas can emerge anywhere, the American ecosystem offers unparalleled resources for growth,” the report said.
“Location choices within America also matter significantly. While California remains the top destination, international founders are increasingly strategic about where they establish operations. Israeli entrepreneurs often favour New York over California, and 15 per cent of all US unicorns have moved their headquarters at least once between founding and reaching billion-dollar valuations.”
Analysis of 191 California-based unicorns revealed that only 38 per cent of their 375,000 employees actually work in California. Nearly a third are employed elsewhere in the US, while another third work overseas, creating a truly international workforce.
When measuring entrepreneurial productivity per capita, Israel leads dramatically with 43.4 unicorn founders per 100,000 first-generation immigrants, followed by New Zealand at 37.3 and Belgium at 24.4. By comparison, India produces 2.5 unicorn founders per 100,000 immigrants, though it still contributes the highest absolute number.
The innovation ecosystem in the US thrives precisely because of this global talent mix, the research noted. With nearly equal numbers of US-born and immigrant founders, researchers describe this as "powerful complementarity".
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.